钆贝葡胺增强MRI检测肝转移瘤:系统评价、Meta分析及与钆塞酸增强MRI的相似性
该系统评价与Meta分析纳入10篇文章共256例患者、562个转移灶,评估钆贝葡胺增强MRI检测肝转移瘤的敏感度和阳性预测值。基于所有可用序列的总体敏感度为95.1%(95%CI 93.1-97.1%),总体阳性预测值为90.9%(95%CI 86.6-95.1%),与纯肝特异性对比剂钆塞酸的报道值相当。
要点
- 联合未增强、动态期及延迟肝胆期成像检测肝转移瘤的敏感度为95.1%。
- 钆贝葡胺增强MRI检测肝转移瘤的总体阳性预测值为90.9%。
- 肝胆期图像较单纯未增强或未增强+动态期可提高肝转移瘤检出。
核心结论
- 钆贝葡胺增强MRI基于所有可用序列评估时,检测肝转移瘤的敏感度和阳性预测值高,与纯肝特异性对比剂钆塞酸的报道值相当。
研究设计与样本
- 系统评价与Meta分析,按PRISMA指南进行,检索EMBASE和PubMed截至2017年12月,纳入10篇文章共256例患者、562个转移灶,以组织病理学、术中观察和/或随访作为完整验证参考标准,采用QUADAS-2工具评估偏倚来源,使用逆方差加权随机效应模型。
诊断标准与关键数值
- 基于所有可用序列(未增强+动态期+延迟肝胆期)检测肝转移瘤的总体敏感度为95.1%(95%CI 93.1-97.1%,15次评估),总体阳性预测值为90.9%(95%CI 86.6-95.1%,11次评估)。
临床应用与阅片要点
- 钆贝葡胺增强MRI可获取注射后即时动态期图像(类似细胞外对比剂)及肝细胞摄取后的延迟肝胆期图像。
- 肝胆期图像较单纯未增强图像或未增强+钆贝葡胺增强动态期图像可提高肝转移瘤检出。
- 基于所有可用序列评估时,钆贝葡胺增强MRI检测肝转移瘤的敏感度为95.1%、阳性预测值为90.9%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the sensitivity and positive predictive value (PPV) of gadobenate-enhanced MR imaging for the detection of liver metastases.
METHODS: This systematic review and meta-analysis was conducted according to PRISMA guidelines. A comprehensive search (EMBASE, PubMed) was performed to identify relevant articles up to December 2017. Studies eligible for inclusion were performed using appropriate methodology with complete verification by means of histopathology, intraoperative observation and/or follow-up, and sufficient information to permit determination of true-positive (TP), false-negative (FN), and false-positive (FP) values. Sources of bias were assessed using the QUADAS-2 tool. An inverse variance-weighted random-effects model was used to obtain sensitivity and PPV estimates. Information was analyzed and presented using Cochran's Q statistic, funnel plots, and modified Deeks' analysis.
RESULTS: Ten articles (256 patients, 562 metastases) were included. Sensitivity estimates for pre-contrast (unenhanced) imaging, gadobenate-enhanced dynamic imaging, and combined unenhanced, dynamic, and delayed hepatobiliary phase imaging for detecting liver metastases on a per-lesion basis were 77.8% (95% CI 71.4-84.3%, 7 assessments), 88.1% (95% CI, 84.0-92.2%, 13 assessments), and 95.1% (95% CI 93.1-97.1%, 15 assessments), respectively. The addition of hepatobiliary phase images significantly improved the detection of liver metastases. The overall PPV was 90.9% (95% CI 86.6-95.1%, 11 assessments). Deeks' funnel analysis revealed no association between sample size and sensitivity (β = 0.02, p = 0.814) indicating no significant publication bias.
CONCLUSIONS: Gadobenate-enhanced MR imaging has high sensitivity and PPV for the detection of liver metastases on a per-lesion basis. The sensitivity and PPV for detection is comparable to reported values for the pure liver-specific agent gadoxetate.
KEY POINTS: • Gadobenate dimeglumine is a hepatobiliary MR contrast agent that permits acquisition of contrast-enhanced liver images during the immediate post-injection dynamic phase, like any extracellular agent, and in the delayed hepatobiliary phase, after specific uptake by the hepatocytes. • The hepatobiliary phase improves detection of liver metastases when compared either to pre-contrast unenhanced images alone or to pre-contrast + gadobenate-enhanced dynamic phase images. • The meta-analysis showed an overall sensitivity of 95.1% and PPV of 90.9% of gadobenate-enhanced MRI for the detection of metastases, when based on the evaluation of all available acquisitions.
引用
- Zhang L, Yu X, Huo L, et al. Detection of liver metastases on gadobenate dimeglumine-enhanced MRI: systematic review, meta-analysis, and similarities with gadoxetate-enhanced MRI. Eur Radiol. 2019. PMID: 30915560. doi:10.1007/s00330-019-06110-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。